Remdesivir: Currently in phase 3 studies.

Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).

Dr. George Martin: My understanding is that there is a fast track phase 3 trial of 1,000 patients here and in China. This is a therapeutic “game changer” based on its success when used in compassionate use outcomes in a limited number of people.  It has a therapeutic window when used in the first 5-10 days before the cytokine storm sets in. Currently IL-6 inhibitor are being studied to attenuate the inflammatory response i.e. “cytokine storm” caused by the immune response in the lung to COVID19
 
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04302766
Contact: Sandi K. Parriot, 301-619-6824, [email protected]
Ages Eligible for Study:  Child, Adult, Older Adult
Sexes Eligible for study:  All

Inclusion Criteria:

• DoD-affiliated personnel (including active and reserve component service members, US civilian employees, contractors, other US personnel, and dependents of any age, as well as allied military forces and local nationals) who have been granted access to the medical facility
• Have a COVID-19 diagnosis
• Available for clinical follow-up for duration of the treatment and follow-up period

 
Exclusion Criteria:
• Unable or unwilling to meet the requirements of the protocol
 
Sponsors/Collaborators: U.S. Army Medical Research and Development Command